All In Biotech

Free tool

FAERS Monitor: Zymaxid

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022548 or its brand name (Zymaxid, Gatifloxacin). Reports on generic versions are filed under their own applications.

Reports

1,785

Serious

1,437

81% of reports

Hospitalization

689

Death reported

106

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypoglycaemia151
  • hyperglycaemia96
  • anaphylactic reaction85
  • drug intolerance83
  • drug ineffective79
  • diarrhoea71
  • eye pain68
  • dizziness58
  • off label use56
  • dyspnoea55
  • rash55
  • nausea50
  • chronic kidney disease47
  • renal failure47
  • blood glucose increased46

Reports by year received

View as table
YearReports
2004299
2005309
2006119
200742
200847
200937
201040
201155
201269
201341
201448
201549
201656
201762
201877
2019100
202062
202151
202253
202340
202439
202541
202649

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,374 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypoglycaemiaSignal15136.831.65,218
hyperglycaemiaSignal9631.125.62,766
anaphylactic reactionSignal8518.214.71,362
eye painSignal6814.211.3824
drug intoleranceSignal8310.18.2677
chronic kidney diseaseSignal477.35.5250
renal failureSignal474.23.1111
blood glucose increasedSignal462.92.255
rash551.51.18
dizziness581.41.16
diarrhoea711.31.05
dyspnoea551.10.91
off label use560.80.64
nausea500.70.64
drug ineffective790.70.610

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.